IDXX · IDEXX Laboratories Inc
Price
Snapshot
50 fields · last close| Market Cap | $44.15B |
| P/E | 38.74 |
| Float | 78.67M |
| Beta | 1.55 |
| Volatility | 38.9% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 78.4 |
| Price | 557.07 |
| Change | −0.59% |
| Prev Close | 560.36 |
| Open | 553.60 |
| Day Low | 552.62 |
| Day High | 566.54 |
| Avg Vol | 1 |
| Avg $ Vol | $338.9M |
| 52W High | 769.98 |
| 52W Low | 500.61 |
| 52W Pos | 21.0% |
| From High | −27.65% |
| From Low | +11.28% |
| Max DD 1Y | −34.17% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +6.38% |
| SMA 50 | +4.08% |
| SMA 200 | −3.90% |
| RSI (14) | 66.0 |
| Vol 30D | 24.1% |
| Vol 90D | 29.4% |
| 1Y Range | 501–770 |
| Daily bars | 536 |
| Perf Week | +8.18% |
| Perf Month | +10.64% |
| Perf Quarter | −0.61% |
| Perf Half Y | −4.90% |
| Perf Year | −12.33% |
| Perf YTD | −16.85% |
| Prev Day | −0.59% |
| Clavix | B+ |
| Debt / Eq | 0.28 |
| Curr Ratio | 1.23 |
| Int Cover | 42.7× |
| FCF Margin | 24.6% |
| Rev Growth | +10.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 23 / 49 |
What IDXX does
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E.
coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups.
In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Clavix risk grade
regraded every trading dayIDXX grades B+, 78.4 of 100. Steadiest on Price Stability (64), most exposed on News Sentiment (59, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 23 of 49 in Health Care by Clavix score.
How rough the ride is
| IDXX | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.55 | 0.84 |
| Volatilityannualized | 38.9% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −34.2% | — |
| Typical daily movemedian absolute daily change | 1.05% | — |
| Days beyond ±3%of the last 252 sessions | 29 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| IDXX | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.55 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| IDXX | |
|---|---|
| 1 week | +8.2% |
| 1 month | +10.6% |
| Year to date | −16.9% |
| 1 year | −12.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| IDXX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 4 Aug |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 2 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| IDXX | |
|---|---|
| Revenue growthyear over year | +10.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openZacks upgraded Idexx Laboratories (IDXX) to a Buy ranking (#2), citing growing optimism about the company's future earnings prospects.
Goldman Sachs raised its rating on IDEXX Laboratories to "strong-buy" in a research note on Friday. No company-specific developments or reasoning were provided in the brief article.
JPMorgan lowered its price target on IDEXX Laboratories shares from $775 to $750 and kept an 'overweight' rating in a research note issued Friday. No reason for the change was given.
IDEXX Laboratories acquired CoVetAI Inc. from private equity firm Chicago Pacific Founders, which announced the exit of its investment. Financial terms of the deal were not disclosed.
IDEXX Laboratories has acquired CoVetAI, a company previously backed by Chicago Pacific Founders' specialist animal health fund. The deal represents the first successful exit from that now-closed fund's inaugural investment vehicle.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
| HUM | Humana Inc | B | $49.61B | 38.79 | 0.67 | Compare |
| EW | Edwards Lifesciences Corp | A- | $49.92B | 49.67 | 0.84 | Compare |
| VEEV | Veeva Systems Inc | B- | $50.25B | 49.52 | 0.88 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.23B | 55.45 | 0.24 | Compare |
| CNC | Centene Corp | B | $34.16B | — | 1.08 | Compare |
| RMD | Resmed Inc | B+ | $33.61B | 22.06 | 0.77 | Compare |
| CAH | Cardinal Health Inc | A- | $58.83B | 34.32 | 0.54 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.